June 2020/21

• French start up pharmaceutical excited about ATX01 for erythromelalgia. Clinical trials for this topical due late 2020

April 1st 2019

• Gabapentin and pregabalin will be classed as controlled drugs in the UK  as from April 1st. See your surgery if concerned.

January 2019

• Genetics and Pain Sensitivity Research Program. The aim of the study is to create a patient registry and learn more about the cause, progression and underlying genetic basis of certain rare diseases – with a particular interest in EM patients/families who do not have the Nav 1.7 mutation. Full details Genetics and Pain Sensitivity Research Program

July 2015

• Xenon announces follow up to the primary genetic study, which will focus on facial EM. Xenon are currently inviting certain participants from the 2013 genetic study to take part in a survey on facial EM. Participants are being asked to fill in an online questionnaire and provide a saliva sample (if requested). This is fantastic move forward for the EM community!  :)

August 2015

• FDA OK a new drug 'Finacea' for Papulopustular Rosacea.

October 2015

• Xenon are still performing free worldwide genetic testing with saliva kit.

November 2015

• 'Tonmya', a drug developed for the treatment of fibromyalgia, could be available end of 2016. For more information http://www.affirmstudy.com/

January 2016

• EM transdermal 'Midodrine' developed by Mayo clinic available through compounding pharmacists.

February 2016

• IMC-1 promising fibromyalgia drug fast tracked by FDA.

March 2016

• New findings potentially provide several new drug targets - CSF1, CSF1 receptor, and DAP12 - that have huge therapeutic potential for neuropathic pain.
  
• Drug candidate ZYN001 that delivers marijuana via skin patch soon to be developed for fibromyalgia.
• Beiersdorf study shows licorice extract can help rosacea.
• CDC release new guidelines for opioid prescribing for chronic pain.

April 2016

• Carbamazepine reduces pain in S241T inherited erythromelalgia mutation. Researchers demonstrate very clearly that it is possible to use genomics and molecular modeling to guide pain treatment. We have the research paper 'Inherited erythromelalgia due to mutations in SCN9A: natural history, clinical phenotype and somatosensory profile' in resources.

EM Warriors Are Partnering With The Mighty!

We're thrilled to announce a new partnership that will bring our resources in front of The Mighty's wide-reaching readership. We will now have a growing home page on The Mighty and appear on many stories on the site.

The Mighty is a story-based health community focused on improving the lives of people facing disease, disorder, mental illness and disability. More than half of Americans are facing serious health conditions or medical issues. They want more than information. They want to be inspired. The Mighty publishes real stories about real people facing real challenges.

We're dedicated to helping people with erythromelalgia in their lives. With this partnership, we'll be able to help even more people.

We encourage you to submit a story to The Mighty and make the voice of an erythromelalgia sufferer heard.

"Here's an example of the kind of stories on The Mighty: To the Person Who Thinks My Fibromyalgia Isn't Real"

The content of the EM Warriors website, including text, graphics, images, information obtained from licensors, and other material, is intended for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.

Please never disregard the advice of your physician or delay seeking it because of something you have read on this website.